Please login to the form below

Not currently logged in
Email:
Password:

Janssen/Jubilant alliance

Janssen Pharmaceutica and Jubilant Discovery Services have agreed a drug discovery partnership covering the field of neuroscience

Janssen Pharmaceutica and Jubilant Discovery Services have agreed a drug discovery partnership covering the field of neuroscience.

The alliance, which will see Jubliant develop preclinical drug clients for Janssen to develop and commercialise, is set to last at least three years.

Jubilant is to receive research funding and is eligible for future milestones and royalties depending on the success of drug candidates.

Financial terms were not disclosed.

"The collaboration will utilise Jubilant's global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centres," said Sri Mosur, CEO and president, global drug discovery and development, Jubilant.

"We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry."

28th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

Keep your audiences close
How getting up close and personal with target audiences can fuel creativity...
The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....

Infographics